(NewsDirect)
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medicalofficer Dr Mark Bleakley speaks with Proactive soon after announcingfinal results for a Phase 1 clinical trial to assess pharmacokineticsand the safety of the company’s anti-inflammatory drug candidateIHL-675A. IHL-675A is a combination cannabinoid drug comprisingcannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dosecombination.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.